Cargando…

Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy

Vaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as a priority group for vaccination, but few stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahmani, Alborz, Dini, Guglielmo, Orsi, Andrea, Sticchi, Laura, Bruzzone, Bianca, Montecucco, Alfredo, Pellegrini, Luca, Manca, Alessia, Domnich, Alexander, Battistini, Angela, Kusznir Vitturi, Bruno, Zacconi, Sonia, Debarbieri, Nicoletta, Icardi, Giancarlo, Durando, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625320/
https://www.ncbi.nlm.nih.gov/pubmed/34835199
http://dx.doi.org/10.3390/vaccines9111269
_version_ 1784606392244502528
author Rahmani, Alborz
Dini, Guglielmo
Orsi, Andrea
Sticchi, Laura
Bruzzone, Bianca
Montecucco, Alfredo
Pellegrini, Luca
Manca, Alessia
Domnich, Alexander
Battistini, Angela
Kusznir Vitturi, Bruno
Zacconi, Sonia
Debarbieri, Nicoletta
Icardi, Giancarlo
Durando, Paolo
author_facet Rahmani, Alborz
Dini, Guglielmo
Orsi, Andrea
Sticchi, Laura
Bruzzone, Bianca
Montecucco, Alfredo
Pellegrini, Luca
Manca, Alessia
Domnich, Alexander
Battistini, Angela
Kusznir Vitturi, Bruno
Zacconi, Sonia
Debarbieri, Nicoletta
Icardi, Giancarlo
Durando, Paolo
author_sort Rahmani, Alborz
collection PubMed
description Vaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as a priority group for vaccination, but few studies have assessed its reactogenicity among the young working age population. An online survey was conducted to investigate the adverse reactions occurring in the 7 days following the first and second vaccination doses amongst resident doctors of the University of Genoa, employed at the IRCCS Ospedale Policlinico San Martino of Genoa, between 11 January and 16 March 2021. A total of 512 resident physicians were invited to participate in the study (female = 53.2%; mean age = 28.9 years), of whom 296 (female = 53.4%, mean age = 28.9 years) and 275 (female = 55.3%, mean age = 29.1 years) completed the survey after their first and second vaccination doses, respectively. In the 7 days following the first dose, most common adverse reactions were local pain (96.3%), fatigue (42.6%), headache (33.8%), arthromyalgia (28.0%), and 5.1% reported fever, while following the second dose, participants reported local pain (93.5%), fatigue (74.9%), headache (57.5%), arthromyalgia (58.2%), and fever (30.9%), with a higher prevalence among females. Systemic (but not local) reactions increased following the second vaccination, reaching severe intensity in 9.8% of participants and causing three or more events of moderate intensity in 23.7% of participants. Adverse reactions preventing regular daily activities could cause absenteeism among workers. These results can be useful to inform populations of young individuals, set expectations, and improve adherence to vaccination campaigns.
format Online
Article
Text
id pubmed-8625320
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86253202021-11-27 Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy Rahmani, Alborz Dini, Guglielmo Orsi, Andrea Sticchi, Laura Bruzzone, Bianca Montecucco, Alfredo Pellegrini, Luca Manca, Alessia Domnich, Alexander Battistini, Angela Kusznir Vitturi, Bruno Zacconi, Sonia Debarbieri, Nicoletta Icardi, Giancarlo Durando, Paolo Vaccines (Basel) Article Vaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as a priority group for vaccination, but few studies have assessed its reactogenicity among the young working age population. An online survey was conducted to investigate the adverse reactions occurring in the 7 days following the first and second vaccination doses amongst resident doctors of the University of Genoa, employed at the IRCCS Ospedale Policlinico San Martino of Genoa, between 11 January and 16 March 2021. A total of 512 resident physicians were invited to participate in the study (female = 53.2%; mean age = 28.9 years), of whom 296 (female = 53.4%, mean age = 28.9 years) and 275 (female = 55.3%, mean age = 29.1 years) completed the survey after their first and second vaccination doses, respectively. In the 7 days following the first dose, most common adverse reactions were local pain (96.3%), fatigue (42.6%), headache (33.8%), arthromyalgia (28.0%), and 5.1% reported fever, while following the second dose, participants reported local pain (93.5%), fatigue (74.9%), headache (57.5%), arthromyalgia (58.2%), and fever (30.9%), with a higher prevalence among females. Systemic (but not local) reactions increased following the second vaccination, reaching severe intensity in 9.8% of participants and causing three or more events of moderate intensity in 23.7% of participants. Adverse reactions preventing regular daily activities could cause absenteeism among workers. These results can be useful to inform populations of young individuals, set expectations, and improve adherence to vaccination campaigns. MDPI 2021-11-03 /pmc/articles/PMC8625320/ /pubmed/34835199 http://dx.doi.org/10.3390/vaccines9111269 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rahmani, Alborz
Dini, Guglielmo
Orsi, Andrea
Sticchi, Laura
Bruzzone, Bianca
Montecucco, Alfredo
Pellegrini, Luca
Manca, Alessia
Domnich, Alexander
Battistini, Angela
Kusznir Vitturi, Bruno
Zacconi, Sonia
Debarbieri, Nicoletta
Icardi, Giancarlo
Durando, Paolo
Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
title Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
title_full Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
title_fullStr Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
title_full_unstemmed Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
title_short Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy
title_sort reactogenicity of bnt162b2 mrna covid-19 vaccine in a young working age population: a survey among medical school residents, within a mass vaccination campaign, in a regional reference teaching hospital in italy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625320/
https://www.ncbi.nlm.nih.gov/pubmed/34835199
http://dx.doi.org/10.3390/vaccines9111269
work_keys_str_mv AT rahmanialborz reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
AT diniguglielmo reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
AT orsiandrea reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
AT sticchilaura reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
AT bruzzonebianca reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
AT montecuccoalfredo reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
AT pellegriniluca reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
AT mancaalessia reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
AT domnichalexander reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
AT battistiniangela reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
AT kusznirvitturibruno reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
AT zacconisonia reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
AT debarbierinicoletta reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
AT icardigiancarlo reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly
AT durandopaolo reactogenicityofbnt162b2mrnacovid19vaccineinayoungworkingagepopulationasurveyamongmedicalschoolresidentswithinamassvaccinationcampaigninaregionalreferenceteachinghospitalinitaly